Successful Use of Bortezomib in an Adolescent with Refractory TTP.

Autor:	Wali, Junaid Ahmad, Quigley, Brian M., Schaefer, Beverly
Předmět:	THROMBOTIC thrombocytopenic purpura BORTEZOMIB REFRACTORY materials TEENAGERS
Zdroj:	Case Reports in Hematology; 11/25/2023, p1-4, 4p
Abstrakt:	With increasing early and upfront use of rituximab and caplacizumab in the modern management of immune-mediated thrombotic thrombocytopenic purpura (iTTP), the risk of refractory disease is expected to decline. However, despite the use of adequate initial therapy, a small subset of patients develop a refractory disease which is difficult to manage. Bortezomib has come to be known as a safe and effective treatment option for refractory iTTP, but its use in children is limited. Here, we describe the case of an adolescent patient with refractory iTTP who had a satisfactory and sustained response to the use of bortezomib. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.